Aaron C. Logan - Concepedia

Author

Aaron C. Logan

University of California, San Francisco ORCID

Also Known As

A C Logan, A Logan, A. Del Rio, A. Logan, A.C. Logan, Aaron C Logan, Aaron C. Logan, Aaron Logan, Alyssa J Logan, Nitin Jain

384

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Stanford University Fred Hutch Cancer Center Memorial Sloan Kettering Cancer Center

About

Aaron C. Logan is an author at University of California, San Francisco specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.7K
2	Health Sciences	10	10	1.1K
3	Blood Transplantation	3	3	66
4	Cell Biology	3	3	148
5	Cardiothoracic Surgery	2	2	36

Aaron C. Logan

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole, The Lancet Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyHematology	2021	721
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy David B. Miklos, Corey Cutler, Mukta Arora, Blood	2017	481
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Christine M. McMahon, Timothy T. Ferng, Jonathan Canaani, Cancer Discovery	2019	412
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study Corey Cutler, Stephanie J. Lee, Sally Arai, Blood	2021	295
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Patrick A. Brown, Bijal Shah, Anjali S. Advani, Journal of the National Comprehensive Cancer Network Hematological MalignancyNccn All PanelMedicinePhiladelphia ChromosomeMixed-phenotype Acute Leukemia	2021	230
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results Bijal Shah, Michael R. Bishop, Olalekan O. Oluwole, Blood	2021	190
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment Aaron C. Logan, Hong Gao, Chunlin Wang, Proceedings of the National Academy of Sciences	2011	171
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia Claire Roddie, Karamjeet Sandhu, Eleni Tholouli, New England Journal of Medicine	2024	145
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival Aaron C. Logan, Nikita Vashi, Malek Faham, Biology of Blood and Marrow Transplantation	2014	136
Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia Aaron C. Logan, Bing Zhang, Balasubramanian Narasimhan, Leukemia	2013	134

Page 1